Peters L J, Withers H R, Thames H D, Fletcher G H
Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):101-8. doi: 10.1016/0360-3016(82)90392-3.
Tumor radioresistance in clinical radiotherapy implies failure to achieve loco-regional disease control with radiation doses producing an acceptable degree of morbidity. Such radioresistance may be a result of many different causes (biological and technical) which are reviewed in terms of possible remedial actions. Dose response relationships for human cancers suggest that in many sites, tumors are heterogenous with respect to their cure-limiting characteristics. The case is developed that unless the predominant cure-limiting factor can be predicted, little benefit may be seen in trails of new treatment strategies using heterogeneous tumor populations. The fundamental problem of clinical radioresistance is therefore perceived as the inability to predictively identify its cause in the individual patient.
临床放射治疗中的肿瘤放射抗性意味着，使用产生可接受程度发病率的辐射剂量无法实现局部区域疾病控制。这种放射抗性可能是由许多不同原因（生物学和技术方面）导致的，本文将根据可能的补救措施对这些原因进行综述。人类癌症的剂量反应关系表明，在许多部位，肿瘤在其治愈限制特征方面是异质性的。有观点认为，除非能够预测主要的治愈限制因素，否则在使用异质性肿瘤群体的新治疗策略试验中可能看不到什么益处。因此，临床放射抗性的根本问题被认为是无法在个体患者中预测性地识别其原因。
